Mangione Pleads Guilty to U.S. Federal Charges Related to Death of UnitedHealthcare CEO
Luigi Mangione pled guilty on Friday to U.S. federal charges related to the death of UnitedHealthcare CEO Brian Thompson.
Federal prosecutors had accused Mangione of traveling to New York City, stalking Thompson, and then shooting him at close range while he walked to an annual investor meeting on 4 December 2024.
In Friday’s hearing at the Thurgood Marshall Courthouse in Manhattan, Mangione pled guilty to one count of interstate stalking resulting in death and one count of stalking through use of interstate facilities resulting in death.
Mangione told the courtroom that he traveled to New York City, posed as an investor in UnitedHealthcare, and emailed the company's leadership to obtain information about a planned investor meeting that Thompson would be at, according to The New York Times, which had reporters at the hearing. Mangione said that UnitedHealthcare responded to his email within an hour, after which he printed a firearm using a 3-D printer and placed a silencer on the device.
“I shot Mr. Thompson in Manhattan,” Mangione said. “I understood that my actions would place him in fear of death or bodily injury. I knew what I was doing was illegal.”
Mangione’s sentencing is scheduled for 18 December 2026. He faces a maximum penalty of life in prison without the chance for parole for each of the stalking charges.
The plea comes just weeks before Mangione is set to go to trial on 8 September for New York state charges related to Thompson’s death. New York prosecutors have charged him with murder in the second degree, which carries a sentence of 25 years to life imprisonment if he is convicted, and several other weapons-related charges. He also faces separate charges in Pennsylvania, where he was arrested, for forgery, carrying a firearm without a license, and other charges. Mangione has pled not guilty to all state charges against him.
Mangione’s legal team has long argued that the federal case and the state cases related to Thompson’s death amount to double jeopardy, which is generally prohibited under the Fifth Amendment of the U.S. Constitution.
“The federal government’s reported decision to pile on top of an already overcharged first-degree murder and state terror case is highly unusual and raises serious constitutional and statutory double jeopardy concerns,” said Karen Friedman Agnifilo, Mangione’s lead attorney, in a statement on 18 December 2024. “We are ready to fight these charges in whatever court they are brought.”
The U.S. Supreme Court, however, has ruled that separate prosecution in state and federal courts does not violate this prohibition. The Associated Press (AP) reports that under New York law, though, the state prosecution against Mangione could be barred if the federal charges against him are resolved first.
“The state’s double jeopardy protections kick in if a jury has been sworn in a prior prosecution, such as a federal case, or if that prosecution ends in a guilty plea,” according to the AP. “Mangione’s cases involve different charges arising from the same course of conduct.”
In the two weeks after Thompson was killed in 2024, UnitedHealthcare’s stock value dropped 20 percent and lost more than $110 billion in market value amidst widespread public outrage about health insurance practices in the United States. The incident prompted a significant reckoning within the business community about how it approaches executive protection for individuals associated with corporate brand identity.
Boards began mandating executive protection measures—not just suggesting them—and companies started beefing-up or contracting out to create formal intelligence programs to inform their executive protection functions.
The incident was a “stark demonstration of how an attack on a key executive can directly impact a company’s market value and overall stability,” Kevin Palacios, CEO, HELPS Latam, shared with Security Management in a prior interview. “Suddenly, many executives in leadership positions worldwide were looking over their shoulders and asking, ‘Could that be me?’ Executive protection was thrust into the spotlight, no longer just a perk for the paranoid but a genuine business continuity issue.”
